Table 1 Characteristics of the study population at baseline
Prospective Cohort | |
|---|---|
N = 50 | |
Age, Mean (SD) | 72.6 (7.35) |
Sex (male), | 36 (72.0%) |
Smoking Exposure, N (%): | |
Never | 18 (36.0%) |
Former smoker | 32 (64.0%) |
Arterial Hypertension, N (%) | 32 (64.0%) |
Dyslipidemia, N (%) | 24 (48.0%) |
Diabetes Mellitus, N (%) | 16 (32.0%) |
Heart Disease, N (%) | 11 (22.0%) |
Echocardiography Pulmonary Hypertension, N (%) | 20 (40.0%) |
Chronic Kidney Failure, N (%) | 5 (10.0%) |
GERD, N (%) | 23 (46.0%) |
Depression-Anxiety, N (%) | 13 (26.0%) |
Malignant Disease, N (%) | 8 (16.0%) |
Obesity (BMI ≥ 30) | 14 (28.0%) |
Thorax HRCT Pattern, N (%): | |
Definite UIP pattern | 23 (46.0%) |
Probable UIP pattern | 17 (34.0%) |
Pattern indeterminate for UIP | 10 (20.0%) |
Emphysema (extension < 15%), N (%) | 10 (20.0%) |
Biopsy, N (%): | |
Cryobiopsy | 3 (6.00%) |
Surgical biopsy | 9 (18.0%) |
Anathomopathological Patterns, N (%): | |
NIU | 9 (75.0%) |
Probable NIU | 3 (25.0%) |
Pulmonary Lung function, Median [Q1;Q3] | |
BMI | 27.0 [26.0;30.0] |
FVC (%) | 94.0 [81.5;104] |
FVC (mL) | 2615 [2085;3168] |
FEV1/FVC | 82.7 [78.2;86.4] |
TLC (%) | 77.0 [67.2;84.5] |
TLC (mL) | 4345 [3228;5040] |
DLCO (%) | 55.0 [46.5;70.0] |
KCO (%) | 82.0 [70.0;94.8] |
6MWD distance (m) | 425 [365;462] |
6MWD minimal SpO2% | 91.0 [87.0;94.0] |
Antifibrotic Treatment, N (%): | |
Pirfenidone | 13 (26.0%) |
Nintedanib | 37 (74.0%) |